MELI vs RAPP · P/E 43, rev $19.01B vs rev $20.0M
MercadoLibre Inc. (MELI) versus Rapport Therapeutics, Inc. Common Stock (RAPP) — a side-by-side from cached financials, not a winner call.
MercadoLibre Inc. (MELI) is a internet retail company listed on NASDAQ.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Latest reported MELI revenue for 2026-06-30 was $19.01B. Net income was $883.0M. MELI currently screens at market cap $82.73B and trailing P/E 43.1.
Latest reported RAPP revenue for 2026-06-30 was $20.0M. Net income was -$76.5M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
MELI currently screens at market cap $82.73B and trailing P/E 43.1. RAPP currently screens at market cap $532.9M.
Not investment advice. Open the MELI and RAPP stock pages for the full models.
Not investment advice.